[	O
Clinical	O
significance	O
of	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
as	O
a	O
prognostic	O
factor	O
of	O
cancer	B-Cancer
disease	O
]	O

Interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
is	O
proinflammatory	O
cytokine	O
that	O
produces	O
multifunctional	O
effects	O
.	O

It	O
is	O
also	O
involved	O
in	O
the	O
regulation	O
of	O
immune	O
reactions	O
,	O
hematopoiesis	O
and	O
inflammatory	O
state	O
.	O

Interleukin	O
-	O
6	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
tumor	B-Cancer
progression	O
including	O
inhibition	O
of	O
cancer	B-Cell
cells	I-Cell
apoptosis	O
and	O
stimulation	O
of	O
angiogenesis	O
.	O

Anti	O
-	O
IL	O
-	O
6	O
therapy	O
is	O
a	O
new	O
strategy	O
in	O
the	O
inflammatory	O
autoimmune	O
diseases	O
and	O
cancer	B-Cancer
.	O

Clinical	O
studies	O
have	O
shown	O
elevated	O
serum	B-Organism_substance
IL	O
-	O
6	O
concentrations	O
in	O
patients	O
with	O
endometrial	B-Cancer
cancer	I-Cancer
,	O
non	B-Cancer
-	I-Cancer
small	I-Cancer
cell	I-Cancer
lung	I-Cancer
carcinoma	I-Cancer
,	O
colorectal	B-Cancer
cancer	I-Cancer
,	O
renal	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
,	O
breast	B-Cancer
and	O
ovarian	B-Cancer
cancer	I-Cancer
.	O

Serum	B-Organism_substance
IL	O
-	O
6	O
levels	O
correlate	O
with	O
tumor	B-Cancer
stage	O
,	O
and	O
survival	O
of	O
patients	O
.	O

In	O
this	O
article	O
we	O
have	O
focused	O
on	O
a	O
role	O
of	O
IL	O
-	O
6	O
as	O
a	O
prognostic	O
factor	O
in	O
several	O
malignancies	B-Cancer
such	O
as	O
colorectal	B-Cancer
cancer	I-Cancer
,	O
breast	B-Cancer
cancer	I-Cancer
,	O
gastric	B-Cancer
cancer	I-Cancer
and	O
pancreatic	B-Cancer
cancer	I-Cancer
.	O

